| | ||
INTERIM RESULTS OF A PHASE 1 STUDY OF RO7062931: A NOVEL LIVER-TARGETED SINGLE-STRANDED OLIGONUCLEOTIDE (SSO) WITHLOCKED NUCLEIC ACID (LNA) THAT TARGETS HBV TRANSCRIPTS | ||
| | ||
| | AASLD 2019 Nov 8-12 Boston Reported by Jules Levin Edward J. Gane1, Cynthia Wat2, Sudip Das2, Bernadette Surujbally2, Christian Schwabe1, Katerina Glavini3, Miriam Triyatni3,Vedran Pavlovic2, Henrik Mueller3, Simon Buatois3 and Joseph Grippo4 1Auckland Clinical Studies, Auckland, New Zealand; 2. Roche Innovation Centre, Welwyn Garden City, UK; 3. Roche Innovation Centre, Basel, Switzerland; 4. Roche Innovation Centre, New York, USA      | |
| | ||
